At Array, we embrace three core values that guide our day-to-day activities
Array markets BRAFTOVI® (encorafenib) capsules in combination with MEKTOVI® (binimetinib) tablets in the United States and with partners in other major worldwide markets. The combination was approved in the U.S. in June 2018.
Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant metastatic colorectal cancer.
Array's pipeline includes several additional programs being advanced by Array or current license-holders, including the following programs currently in registration trials:
Selumetinib (partnered with AstraZeneca)
Ipatasertib (partnered with Genentech)
LOXO-292 (partnered with Eli Lilly)
Tucatinib (partnered with Seattle Genetics)
Vitrakvi® (larotrectinib, partnered with Bayer AG) is approved in the United States, and Ganovo® (danoprevir, partnered with Roche) is approved in China.
Our aim is to continue to bring promising therapies to patients in need.
As our portfolio grows, so does our commitment to patients. We are taking creative approaches to ensure that our patient and caregiver communities have the access and support they need to treat diseases where there is a high unmet need.
Vitrakvi® is a registered trademark of Bayer AG.